Skip to main content Accessibility help

Assessing Data Sources for Medicine Price Studies

  • Sabine Vogler (a1) and Peter Schneider (a1)



There is no established methodology to assess the feasibility of medicine price data sources. Against this backdrop, a framework to guide the selection of most appropriate price data sources for pharmacoeconomic research has been developed.


A targeted literature review was carried out. Dimensions discussed in literature as relevant for medicine price comparisons and practical experience of the authors in medicine price studies informed the conceptional work of the framework development. A draft version of the framework was reviewed by peer pricing experts. The feasibility of the framework was tested in case studies.


According to the developed framework (called Re-ADAPT), a medicine price data source should meet the following criteria: reliability and sustainability; accessibility at a cost that users can afford; provision of medicine price information at the date(s) required; information for the defined geographic area, or at least in a representative way; coverage of the pharmaceuticals and at the price type(s) required. Easy handling and provision of additional information were defined as supportive assets of candidate data sources (secondary criteria). The case studies confirmed the feasibility of the Re-ADAPT framework. In some cases, however, it can be difficult to disentangle assessment criteria (particularly geographic area, scope of pharmaceuticals and price types) for separate consideration, given their interlinkage.


While selection of the most appropriate data sources will remain a challenge, the Re-ADAPT framework aims to provide practical guidance and thus contribute to a more careful, balanced, and evidence-based selection of data sources for medicine price studies.


Corresponding author

Author for correspondence: Sabine Vogler, Email:


Hide All
1.Drummond, MF, Wilson, DA, Kanavos, P, Ubel, P, Rovira, J (2007) Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23, 3642.
2.Henshall, C, Mardhani-Bayne, L, Fronsdal, KB, Klemp, M (2011) Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care 27, 253260.
3.Henshall, C, Schuller, T (2013) Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care 29, 353359
4.WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. (2016) Glossary of pharmaceutical terms. Update 2016. Vienna.
5.Andersson, F (1993) Methodological aspects of international drug price comparisons. Pharmacoeconomics 4, 247256.
6.Danzon, PM, Kim, JD (1998) International price comparisons for pharmaceuticals. Pharmacoeconomics 14, 115128.
7.Machado, M, O'Brodovich, R, Krahn, M, Einarson, TR (2011) International drug price comparisons: Quality assessment. Rev Panam Salud Publica 29, 4651.
8.WHO, HAI (2003) Medicine prices. A new approach to measurement. Working draft for field testing and revision. Geneva: World Health Organization, Health Action International.
9.WHO, HAI (2008) Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization, Health Action International.
10.Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems.
11.World Health Organization (2017) Medicine price information sources.
12.Hinsch, M, Kaddar, M, Schmitt, S (2014) Enhancing medicine price transparency through price information mechanisms. Global Health 10, 34.
13.Walley, T, Folino-Gallo, P, Barry, M, et al. (2006) The EurMedStat proposals on indicators for price and utilisation. Ital J Public Health 3, 1521.
14.World Health Organization. Medicine price information sources.
15.Panteli, D, Arickx, F, Cleemput, I, et al. (2016) Pharmaceutical regulation in 15 European countries. Review. Health Syst Transit 18, 1118.
16.Busse, R, Panteli, D, Schaufler, J, Schröder, H (2016) Europäischer Preisvergleich für patentgeschützte Arzneimittel [European Price Comparision for On-Patent Medicines]. Berlin: Springer.
17.Wagner, JL, McCarthy, E (2004) International differences in drug prices. Annu Rev Public Health 25, 475495.
18.Petrou, P, Talias, MA (2016) Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: A comparative study among five European recession countries, from a Cyprus perspective. J Pharm Policy Pract 9, 1.
19.World Health Organization (2013) WHO guideline on country pharmaceutical pricing policies. Geneva: WHO.
20.Vogler, S, Habl, C, Bogut, M, Voncina, L (2011) Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J 52, 197.
21.Vogler, S, Zimmermann, N, Habimana, K (2014) Study of the policy mix for the reimbursement of medicinal products. Proposal for a best practice-based approach based on stakeholder assessment. Vienna: Commissioned by the European Commission.


Type Description Title
Supplementary materials

Vogler and Schneider supplementary material
Vogler and Schneider supplementary material 1

 Unknown (88 KB)
88 KB

Assessing Data Sources for Medicine Price Studies

  • Sabine Vogler (a1) and Peter Schneider (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed